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Abstract 
Background: Haemoglobin S (HbS) is the gene known to confer the strongest advantage against malaria morbidity 
and mortality. Multiple HbS effects have been described resulting in protection against parasitaemia and reduction 
of severe malaria risk. This study aimed to explore HbS protection against severe malaria and Plasmodium falciparum 
parasitaemia in Angolan children exhibiting different severe malaria syndromes.
Methods: A case–control study was designed with 430 malaria cases (n = 288 severe malaria and n = 142 uncom‑
plicated malaria) and 319 uninfected controls, attending a central paediatric hospital in Luanda. Severe malaria syn‑
dromes were cerebral malaria (n = 130), severe malaria anaemia (n = 30) and hyperparasitaemia (n = 128). Quantita‑
tive trait locus analysis was carried out to study HbS association to parasite densities.
Results: Previously reported HbS protection against severe malaria was confirmed in case–control analysis 
(P = 2 × 10−13) and corroborated by transmission disequilibrium test (P = 4 × 10−3). High parasite density protection 
conferred by HbS was detectable within severe malaria patients (P = 0.04). Stratifying severe malaria patients accord‑
ing parasite densities, it was found that HbS was highly associated to hyperparasitaemia protection (P = 1.9 × 10−9) 
but did not protect non‑hyperparasitaemic children against severe malaria complications, namely cerebral malaria 
and severe malaria anaemia. Many studies have shown that HbS protects from severe malaria and controls parasite 
densities but the analysis further suggests that HbS protection against severe malaria syndromes was at a large extent 
correlated with control of parasitaemia levels.
Conclusions: This study supports the hypothesis that HbS confers resistance to hyperparasitaemia in patients exhib‑
iting severe malaria syndromes and highlights that parasitaemia should be taken into account when evaluating HbS 
protection in severe malaria.
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Background
The haemoglobin S mutation (HbS) is very well recog-
nized as the human single gene conferring the strongest 
advantage against falciparum malaria [1, 2]. Evidence 
from HbS genetic association studies in African coun-
tries with malaria endemicity levels, helped to settle the 
notion that epidemiology of sickle-cell trait results from 
the selective pressure imposed on the human genome by 
Plasmodium infection [3–8]. Multiple biochemical and 
immune mechanisms have been suggested to explain 
Open Access
*Correspondence:  rsambo@gmail.com 
1 Instituto Gulbenkian de Ciência, Oeiras, Portugal
Full list of author information is available at the end of the article
Page 2 of 8do Sambo et al. Malar J  (2015) 14:393 
HbS protection against Plasmodium falciparum patho-
genesis and morbidity. It is proposed that such mecha-
nisms act concurrently to improve parasitaemia control 
and protect from uncomplicated and severe malaria [9].
In Angola, sickle-cell disease is a critical public health 
concern and is considered a main contributor to the high 
mortality rate in children [10, 11]. However, there are few 
reports on HbS prevalence in Angolan populations [12–
14]. Malaria is one of the leading causes of morbidity and 
mortality in Angola, mainly among preschool children, 
and it is estimated that P. falciparum causes 90 % of all 
malaria infections [11, 15–17].
This study aimed to analyse the role of HbS mutation 
in malaria protection in Angolan children, according to 
disease severity and degree of infection. The results of 
this stratified analysis suggest that HbS carriers exhibit-
ing severe malaria syndromes are significantly protected 
against hyperparasitaemia.
Methods
Place of study and ethical permission
Luanda is an endemic-malaria province with high level of 
transmission [18]. Hospital Pediátrico David Bernardino 
(HPDB) is a tertiary national reference paediatric hospi-
tal in Luanda, Angola. Ethical permission for this study 
was granted by the Ethics Committee of the HPDB in 
Luanda that was appointed by the Angolan Ministry of 
Health.
Subjects
A total of 749 children, living in Luanda and ranging from 
6 months to 13 years of age, were enrolled in the present 
study. Cases and controls were selected among attend-
ance to the HPDB. The sample collection was carried 
out from February 2005 to May 2007 and comprised 288 
severe malaria children (130 with cerebral malaria and 
158 with severe malaria but not cerebral malaria), 142 
patients with uncomplicated malaria and 319 uninfected 
controls. Samples were also collected from mothers of 
severe malaria children and comprised 226 mother–child 
pairs. Mothers were enrolled only after written, informed 
consent and children were enrolled only after written, 
informed consent from their parents or guardians.
Phenotypic and inclusion criteria
Malaria was diagnosed on the basis of a positive asexual 
parasitaemia detected by a single reader on a Giemsa-
stained thick film. For parasitaemia quantification 100 
high-power microscopic fields were observed. The num-
ber of asexual parasites and white blood cells (WBCs) 
were counted in each field until the number of WBCs 
reached 200 and the parasite density was calculated from 
this value [19]. To confirm and select for P. falciparum 
infection, children with mixed infections, as ascertained 
by malaria species-specific nested-PCR in peripheral 
blood DNA [20], were excluded from the study. Triage 
and clinical examinations of patients with severe disease 
included a clinical history collected upon admission to 
the paediatrics urgency ward, followed by detailed clini-
cal examination as described below.
Clinical criteria
The diagnosis of cerebral malaria followed the criteria 
of the WHO definition, strictly for research purposes, 
valuing unarousable coma, which was defined by the 
inability to localize painful stimuli in absence of other 
causes of encephalopathy [21]. For the purposes of this 
study, whenever coma has been preceded by a seizure 
the assessment of coma was made 1 h after the end of the 
seizure. This procedure is meant to exclude transitional 
post-convulsive coma.
The cerebral malaria patients had to meet all the fol-
lowing criteria: (1) coma score <3 in the Blantyre Scale, 
for children younger than 60 months or score <7 on the 
Glasgow Scale, for children aged equal or more than 
60  months; (2) absence of diagnostic criteria for any 
other possible cause of encephalopathy, including hypo-
glycaemia (venous blood glucose below 40  mg/dL); (3) 
exclusion of meningitis-cerebrospinal fluid without 
pleocytosis (up to 8  lymphocytes/cu mm) nor hypogly-
corrachia (determination of glucose in cerebrospinal 
fluid >50 mg/dL or equal to 50 % of blood glucose, never 
<40 mg/dL).
Severe malaria anaemia (SMA) was defined as hae-
moglobin <5  g/dL or haematocrit <15  % and hyperpar-
asitaemia (HP) required a value of parasitaemia >100 
parasitized erythrocytes per microscopic field (magni-
fication 1000×). The presence of any diagnosis or any 
other neurological sign, including seizures, installed dur-
ing the course of the disease excluded the child from the 
study.
Uncomplicated malaria patients had no clinical mani-
festations suggestive of complications of malaria, as 
well as any other pathology that could explain a febrile 
syndrome.
Controls were uninfected children randomly selected 
in the vaccination ward of the HPDB. Children in this 
group had no symptom of disease and were negative in a 
PCR test for Plasmodium DNA performed in peripheral 
blood.
Blood DNA preparation
DNA was extracted from peripheral blood using the 
Chemagen Magnetic Bead Technology in an auto-
mated nucleic acid isolation station. DNA preparations 
were quantified using PicoGreen reagents (Invitrogen®) 
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according to the supplier instructions. The dbSNP, rs334, 
that defines the HbS mutation, was genotyped with the 
Mass Array system to design multiplex reactions for PCR 
and iPlex primer extension (Sequenom) and the MALDI-
TOF based Mass Array genotype platform (Sequenom). 
Genotyping rate was higher than 90 %.
Phenotypic data analysis
The statistical analysis for sample characterization was 
performed with SPSS version 15.0. The data that were 
not normally distributed were analysed using non-para-
metric methods (Mann–Whitney U and Kruskal–Wallis) 
and Pearson Chi square was used to study the association 
between qualitative variables. A threshold for statistical 
significance was P < 0.05; odds ratios (OR) and 95 % con-
fidence interval were calculated to measure the magni-
tude of association.
Logistic regression was performed with parasitaemia 
as a dependent variable dichotomized as <100 and ≥100 
parasitized erythrocyte/microscopic field using diagnosis 
and age group in bivariate analysis.
Genetic analysis
Hardy–Weinberg equilibrium requirements (P  >  0.05) 
were met in uninfected controls. Case–control asso-
ciation analysis was performed with the logistic regres-
sion model implemented in the SNPassoc package for R 
software (version 2.7.0) using allelic and genotypic fre-
quencies where dichotomized disease outcomes were 
analysed as variables dependent on presence of allele T 
or presence of genotype AT. Genotypic analysis used the 
dominant and additive genetic models which are differ-
ent from the actual underlying mode of inheritance of the 
minor allele [22]. The significance level of the likelihood 
ratio test P < 0.05 was considered as suggestive evidence 
for association. TRANSMIT software that allows TDT 
testing when phase is unknown was used [23] to analyse 
HbS transmission in mother–child pairs. Quantitative 
trait analysis (QTL) of parasite densities was performed 
with the program Plink (version 1.06) that calculates 
the level of significance, either by using the asymptotic 
model, or the empirical model [24]. QTL analysis consid-
ered the additive linear model where the parasite density 
is analysed as a continuous variable dependent on the 
HbS genotype status (AA, AT and TT).
Results
Sample characterization
In this hospital-based study, association analyses of the 
HbS mutation (dbSNP rs334) was performed in Angolan 
children with distinct malaria phenotypes with the pri-
mary purpose of stratifying the HbS genetic effect accord-
ing malaria clinical traits. The study entailed 430 malaria 
patients and 319 uninfected control children. All patients 
were enrolled at the HPDB in Luanda and were clini-
cally evaluated as described in the “Methods”. The patient 
group was composed of 142 patients with uncomplicated 
malaria (UM) phenotype and 288 patients with severe 
malaria (SEV). When analyzing the clinical phenotype 
of the SEV patients it was found that only a part of them 
had criteria for defining cerebral malaria (CM), which 
justified the separation into two distinct groups, such 
as CM (n =  130) and severe malaria with SMA and/or 
HP but no symptoms of CM (n = 158). However, in each 
group it was found that there was overlap of additional 
complications identified as follows: CM/SMA (7.6  %), 
CM/HP (10.7  %), SMA/HP (19.1  %), and CM/SMA/HP 
(5.2  %) (Fig.  1). Within the group of SEV patients 202 
had hyperparasitaemia and 86 had low parasitaemia lev-
els (nHP). Patients with UM were outpatients, whereas 
the SEV patients were hospitalized. Uninfected controls 
(UIF) were recruited from the Department of Vaccina-
tion of HPDB that proceeded from the same population.
Kimbundu, the predominant ethnic group in Luanda 
was the most represented in the sample (50.7 %) followed 
by the Umbundu group (13.7 %). This ethnic representa-
tion did not differ in UM, SEV and UIF patient groups 
(Chi square test, P =  0.46). Although male gender pre-
vailed in all groups (Table 1), no significant sex bias was 
found across malaria and control groups (Chi square test, 
P = 0.17). The distribution of age groups in SEV and UM 
patients (Fig.  2) were comparable with median values 
of 43 and 39.5  months, respectively. No significant dif-
ferences were found in age distribution of SEV, UM and 
UIF groups as evaluated by the Mann–Whitney U-test 
(P = 0.14). Median value of parasite densities was higher 
in the age group 13–59 months and multiple comparison 
by Kruskall–Wallis test revealed that parasitaemia den-
sities differed across age groups (P  =  0.003). However 
logistic regression with parasitaemia and age groups was 
not significant (P = 0.10). The fatality rate in SEV patients 
was 13 % and was significantly higher in CM patients as 
compared to the severe non-cerebral malaria cases (Chi 
square test, P = 3 × 10−3), [OR 1.89 (2.33–1.54)].
HbS effects in clinical malaria
The role of the HbS mutation in different clinical malaria 
traits was studied to determine whether the sample rep-
licated the expected malaria protective effect. Predict-
ably, the T allele at dbSNP rs334 (HbS mutation) was 
significantly under-represented in SEV patients (3.7  %) 
as compared to UM patients (10.9  %) and to UIF con-
trols (15.1  %) (Table  2). These allelic differences were 
reflected on the heterozygous genotype frequency that 
was remarkably low in severe malaria (1.5  %) as com-
pared to age-matched general population (23.7  %) 
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suggesting that sickle cell trait had a stronger protection 
effect against SEV [OR 0.15 (0.09–0.27)] than against UM 
[OR 0.50 (0.30–0.84)] (Table  2). The transmission dis-
equilibrium test (TDT) showed a significant reduction 
in transmission of HbS allele (T allele) to children with 
SEV (P = 0.002) (Table 3). The TDT result supported the 
notion that absence of HbS favours the development of 
SEV and corroborates the results of case–control analy-
sis lessening the possibility of population stratification 
effects. It is noteworthy that HbS conferred strong pro-
tection against CM and against non-cerebral forms of 
SEV, suggesting that protection against SEV was irre-
spective of CM development (Table 2).
HbS controls parasite density in severe malaria
Next, it was explored whether HbS protection against 
SEV correlated with control of parasitaemia lev-
els. Median parasitaemia levels in all malaria patients 
(UM + SEV) were lower in presence of HbS (Fig. 3) and 
after UM exclusion this effect was also observed in SEV 
patients (Fig.  4). This observation was corroborated 
by QTL analysis as it was found that HbS best fitted an 
additive mode of action in the reduction of the parasite 
density in children with malaria, irrespective of dis-
ease severity (Table 4). Albeit the low HbS frequency in 
SEV children reduces statistical power, the QTL analysis 
has detected a significant HbS effect in protecting SEV 
patients against hyperparasitaemia (Table 4).
To determine whether the protection against SEV afforded 
by HbS was conditioned to the parasitaemia status, SEV 
patients were grouped as hyper-parasitaemic (HP, parasitae-
mia ≥100) and non-hyperparasitaemic (nHP, parasitaemia 
<100), irrespective of other observed clinical complications.
HbS allelic frequency was higher in non-hyperpar-
asitaemic children suggesting that HbS protects SEV 
patients from developing hyperparasitaemia (Table  5). 
Thus, seven out of nine SEV patients carrying the HbS 
allele did not show hyperparasitaemia.
Allelic association analysis stratified for parasitaemia 
showed that HbS strongly protects against SEV occurring 
with HP but did not confer overt advantage against SEV 
in nHP children (Table 5). Together, these results imply 
that strong protection afforded by HbS against severe 
malaria in this cohort is coupled to hyperparasitaemia 
resistance and further suggest that other factors are con-
trolling susceptibility/resistance to non-hyperparasitae-
mic severe malaria.
Fig. 1 Co‑occurrence of malaria complications in severe malaria 
patients. Venn diagram representing the overlap of specific clinical 
malaria manifestations (cerebral malaria, hyperparasitaemia and 
severe anaemia) in 288 severe malaria patients
Table 1 Gender representation in malaria patients and uninfected controls
Gender Severe malaria Uncomplicated malaria Uninfected controls Total
Male (n) (%) 172 (59.7 %) 75 (52.8 %) 179 (56.1 %) 426 (56.9 %)
Female (n) (%) 116 (40.3 %) 67 (47.2 %) 140 (43.9 %) 323 (43.1 %)
Total 288 142 319 749
Fig. 2 Clinical phenotypes and age groups in months
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Discussion
The mechanism of HbS protection against P. falciparum 
morbidity remains controversial [25–27]. Studying a sam-
ple of Angolan children with different malaria syndromes 
collected evidence showed that HbS conferred specific 
protection against hyperparasitaemia, specifically in the 
context of severe malaria. In this study population, a 
significant number of malaria patients (42  %) exhibited 
concomitantly different malaria clinical complications. 
These overlapping malaria syndromes corroborate the 
Table 2 HbS allelic and genotypic frequency (AT for dbSNP rs334) and genetic association to uncomplicated and severe 
malaria
The numbers for SEV, UM and UIF represent only those with successful genotyping
SEV severe malaria, UM uncomplicated malaria, UIF uninfected, CM cerebral malaria, SnC severe non-cerebral malaria
a Performed with the dominant genetic model comparing A/A genotypic frequencies to A/T and T/T frequencies
Genetic testing SEV UM UIF UM/UIF SEV/UIF CM/UIF SnC/UIF
n = 263 (%) n = 141 (%) n = 304 (%) P P P P
OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
Allelic 3.7 10.9 15.1 9 × 10−2 6 × 10−11 9 × 10−4 3 × 10−6
0.69 (0.45–1.07) 0.22 (0.13–0.36) 0.26 (0.11–0.61) 0.31 (0.17–0.54)
Genotypica 1.5 8.5 23.7 7 × 10−3 2 × 10−13 1 × 10−9 4 × 10−8
0.50 (0.30‑0.84) 0.15 (0.09‑0.27) 0.11 (0.04‑0.28) 0.19 (0.30‑0.84)
Table 3 HbS transmission disequilibrium test in  226 
mother-severe malaria child pairs
Observ observed transmissions, Expec expected transmissions, Var (O–E) variance 
(observed-expected)
Allele Observ Expec Var (O–E) P value
T 20 30.4 9.9 0.001
A 432 421.6 9.9 0.001
Fig. 3 Parasitaemia distribution stratified by HbS genotype. Plot 
represents parasite densities in all malaria patients (n = 288). HbS 
genotypes are represented heterozygous (AT) and non‑carriers (AA). 
Parasite density represents the number of parasitized erythrocytes/
microscopic field. Data are represented in boxes that include 50 % 
of sample distributions (2nd and 3rd quartiles) with horizontal lines 
(median) and outliers are represented by circles
Fig. 4 Parasitaemia distribution stratified by HbS genotype. Plot 
represents parasite densities only in the sub‑set of severe malaria 
patients (cerebral malaria, severe anaemia and hyperparasitaemia). 
HbS genotypes are represented heterozygous (AT) and non‑carriers 
(AA). Parasite density represents the number of parasitized erythro‑
cytes/microscopic field. Data are represented in boxes that include 
50 % of sample distributions (2nd and 3rd quartiles) with horizontal 
lines (median) and outliers are represented by circles
Table 4 Parasite density QTL analysis for HbS
The results refer to QTL analysis using the additive model
BETA is the regression coefficient; confidence intervals (L95 and U95)
UM uncomplicated malaria, SEV severe malaria
Patients BETA L95 U95 P value
UM + SEV −87.57 −142.3 −32.84 0.002
SEV −127.1 −209.1 −45.09 0.04
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notion that severe malaria cases often represent clinical 
syndromes rather than clinical isolated entities [28]. In 
this context, studying HbS protection against one clinical 
condition faces possible confounding by co-occurrence 
of other infection parameters. Strikingly, by contrasting 
allelic and genotypic HbS frequencies in severe malaria 
patients stratified either for parasitaemia values or by 
other causes of clinical severe malaria (namely, cerebral 
malaria and/or severe malaria anaemia), it was found that 
protection against severe malaria was at a large extent 
attributable to resistance to hyperparasitaemia. Although 
with limitations due to the reduced number of HbS 
homozygotes the analysis supports the notion that con-
trol of parasite density was quantitatively dependent on 
the number of T alleles.
Furthermore, HbS showed to control quantitatively 
parasitaemia in clinical malaria both in presence or 
absence of uncomplicated malaria cases. This result sug-
gests that HbS contributes to resistance to expansion of 
blood stage parasite irrespective of malaria clinical pres-
entation. Indeed, these results sustain the debate around 
the effect of HbS protection against hyperparasitaemia 
and its mechanisms. An experimental cerebral malaria 
(ECM) study in mice expressing sickle haemoglobin con-
cluded that the protective effect exerted against lethal 
ECM was irrespective of parasite load [25]. Meanwhile, 
a human study evidenced that median parasite densities 
were significantly higher in  APOE  ε4 children for  Plas-
modium  spp. densities compared to non-APOE  ε4 chil-
dren and concluded a suggestive epistatic interaction 
between APOE and HbS genes such that sickle cell trait 
only had an effect on parasite density in APOE ε4 chil-
dren [27].
The predominant occurrence of severe malaria in chil-
dren under 5  years of age in the study sample is in line 
with what is reported in other areas of stable malaria 
[29, 30]. It has been argued, that lower frequency of 
severe malaria as well as decreased parasitaemia at both 
extremes of the age distribution could reflect, on one 
hand, the protective role of maternal immunity in chil-
dren under 18 months and, on the other hand, the acqui-
sition of immunity with age in children older than 9 years 
[31, 32]. Nevertheless, it cannot be ruled out that uneven 
representation of hyperparasitaemia and severe malaria 
across the distribution age may have an impact on HbS 
protection effects here identified.
The HbS allele frequency in the uninfected control 
group was 15.1 %, similar to that of the HapMap Yoruba 
(Nigeria) sample where the frequency is 12.5  %, though 
HbS frequency may exceed 20 % in other African popu-
lations [33]. Case–control analysis demonstrated a 
stronger protective effect of the HbS allele against severe 
malaria syndromes (OR = 0.15) as compared to uncom-
plicated malaria (OR = 0.50). Studies in Kenya reported 
similar genetic effects on protection against uncompli-
cated malaria (OR  =  0.50) and against severe malaria 
(OR  =  0.17) [6]. This strong protection against severe 
malaria conferred by the heterozygous HbAS was also 
clearly confirmed with a case–control study of 2591 
severe falciparum malaria children enrolled at a tertiary 
referral center in Ghana (OR = 0.08) [34]. Another study 
that followed a cohort of 1070 children in Ghana showed 
protection against high parasitaemia in uncomplicated 
malaria [35]. It is worth mentioning that similarly to this 
Angolan sample, the protective effect of the HbS allele 
was evaluated in case–control supplemented with TDT 
[36] and was not diluted in a genome-wide association 
study of severe malaria, despite the ethnic diversity of the 
Gambian population [2].
The results of the present study reinforce the notion 
that parasitaemia levels are to be taken into account on 
evaluation of HbS protection in severe malaria. Never-
theless, the mechanism of HbS protection against hyper-
parasitaemia was not addressed in this study leaving open 
the possibility that HbS may partially accelerate the pro-
cess of immunity acquisition against P. falciparum [37].
Table 5 HbS allelic and genotypic frequency (TA for dbSNP rs334) and severe malaria association HbS conditioned to par-
asitaemia levels
The numbers for HP and nHP represent only those with successful genotyping
HP hyperparasitaemia, nHP non-hyperparasitaemia, UM uncomplicated malaria, UIF uninfected
a Performed with the dominant genetic model comparing A/A genotypic frequencies to T/A and T/T frequencies
Genetic testing HP nHP HP/UM nHP/UM HP/UIF nHP/UIF
n = 178 (%) n = 110 (%) P P P P
OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
Allelic (T) 1.1 6.4 1.8 × 10−7 0.13 4.9 × 10−9 0.16
0.11 (0.04–0.30) 0.53 (0.24–1.21) 0.10 (0.04–0.26) 0.67 (0.38–1.18)
Genotypica 1.1 1.8 1 × 10−4 0.23 1. 9 × 10−6 1. 6 × 10−2
0.19 (0.08–0.48) 0.55 (0.21–1.45) 0.11 (0.04–0.27) 0.42 (0.20–0.85)
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Conclusion
Although these findings should be evaluated with cau-
tion due to sample size, they suggest that HbS does 
not significantly reduce the risk of developing clini-
cal forms of severe malaria syndrome not entailing 
hyperparasitaemia and that the risk of co-occurrence 
of cerebral malaria or severe anaemia and hyperpara-
sitaemia is higher in non-carriers. Thus, this study 
supports the hypothesis that HbS confers resistance 
to hyperparasitaemia in patients exhibiting severe 
malaria syndromes.
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